Ingalls & Snyder LLC Vericel Corp Transaction History

Ingalls & Snyder LLC

$2.55 Billion
Q4 2024

A detailed history of Ingalls & Snyder LLC transactions in Vericel Corp stock. As of the latest transaction made, Ingalls & Snyder LLC holds 19,581 shares of VCEL stock, worth $902,096. This represents 0.04% of its overall portfolio holdings.

Number of Shares

19,581

Previous 20,781 5.77%

Holding current value

$902,096

Previous $878,000 22.44%

% of portfolio

0.04%

Previous 0.03%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Jan 29, 2025	SELL	$40.05 - $59.11 $48,060 - $70,932	-1,200 Reduced 5.77%	19,581 $1.08 Million
Q3 2024 Nov 14, 2024	SELL	$42.25 - $53.56 $6,337 - $8,034	-150 Reduced 0.72%	20,781 $878,000
Q1 2024 May 13, 2024	SELL	$32.52 - $52.33 $5,853 - $9,419	-180 Reduced 0.85%	20,931 $1.09 Million
Q4 2023 Jan 29, 2024	SELL	$30.85 - $37.09 $10,489 - $12,610	-340 Reduced 1.59%	21,111 $752,000
Q3 2023 Nov 02, 2023	SELL	$31.69 - $39.25 $49,119 - $60,837	-1,550 Reduced 6.74%	21,451 $719,000
Q2 2023 Jul 27, 2023	SELL	$29.0 - $38.37 $24,650 - $32,614	-850 Reduced 3.56%	23,001 $864,000
Q1 2023 May 09, 2023	SELL	$23.85 - $31.34 $79,897 - $104,989	-3,350 Reduced 12.32%	23,851 $699,000
Q4 2022 Jan 31, 2023	SELL	$17.65 - $27.37 $150,995 - $234,150	-8,555 Reduced 23.93%	27,201 $716,000
Q3 2022 Oct 21, 2022	SELL	$22.62 - $32.54 $15,834 - $22,778	-700 Reduced 1.92%	35,756 $830,000
Q2 2022 Aug 11, 2022	SELL	$22.88 - $39.45 $34,548 - $59,569	-1,510 Reduced 3.98%	36,456 $918,000
Q1 2022 May 09, 2022	SELL	$31.69 - $43.29 $38,028 - $51,948	-1,200 Reduced 3.06%	37,966 $1.45 Million
Q4 2021 Feb 11, 2022	SELL	$35.2 - $52.6 $167,552 - $250,376	-4,760 Reduced 10.84%	39,166 $1.54 Million
Q3 2021 Oct 27, 2021	SELL	$46.35 - $59.75 $60,857 - $78,451	-1,313 Reduced 2.9%	43,926 $2.14 Million
Q2 2021 Aug 03, 2021	SELL	$47.2 - $67.81 $159,064 - $228,519	-3,370 Reduced 6.93%	45,239 $2.38 Million
Q1 2021 Apr 21, 2021	SELL	$30.93 - $59.48 $47,941 - $92,194	-1,550 Reduced 3.09%	48,609 $2.7 Million
Q4 2020 Jan 27, 2021	SELL	$18.53 - $31.5 $17,788 - $30,240	-960 Reduced 1.88%	50,159 $1.55 Million
Q3 2020 Oct 21, 2020	SELL	$14.68 - $19.12 $45,508 - $59,272	-3,100 Reduced 5.72%	51,119 $947,000
Q2 2020 Jul 31, 2020	SELL	$8.5 - $15.82 $3,400 - $6,328	-400 Reduced 0.73%	54,219 $749,000
Q1 2020 Apr 22, 2020	SELL	$7.25 - $19.22 $24,563 - $65,117	-3,388 Reduced 5.84%	54,619 $501,000
Q4 2019 Jan 15, 2020	SELL	$13.77 - $19.2 $17,143 - $23,904	-1,245 Reduced 2.1%	58,007 $1.01 Million
Q3 2019 Oct 16, 2019	SELL	$14.93 - $19.83 $24,485 - $32,521	-1,640 Reduced 2.69%	59,252 $897,000
Q2 2019 Jul 11, 2019	SELL	$15.01 - $18.89 $7,865 - $9,898	-524 Reduced 0.85%	60,892 $1.15 Million
Q1 2019 Apr 11, 2019	SELL	$16.23 - $20.29 $3,246 - $4,058	-200 Reduced 0.32%	61,416 $1.08 Million
Q4 2018 Jan 24, 2019	BUY	$10.77 - $18.44 $84,501 - $144,680	7,846 Added 14.59%	61,616 $1.07 Million
Q3 2018 Oct 24, 2018	SELL	$9.1 - $14.8 $10,920 - $17,760	-1,200 Reduced 2.18%	53,770 $761,000
Q2 2018 Aug 10, 2018	BUY	$9.6 - $14.6 $527,712 - $802,562	54,970 New	54,970 $533,000

Others Institutions Holding VCEL

# of Institutions

292

Shares Held

49.4M

Call Options Held

98.2K

Put Options Held

135K

View Full List

About Vericel Corp

Ticker VCEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,178,000
Market Cap $2.17B
Description
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for t...

More about VCEL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ingalls & Snyder LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ingalls & Snyder LLC with notifications on news.

Account

Ingalls & Snyder LLC Vericel Corp Transaction History